Overview

A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy

Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Hetrombopag in secondary prevention of thrombocytopenia caused by lung cancer treatment
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
hetrombopag